Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Marinomed Biotech
Its shares trade on Wiener Börse under the ticker MARI.VI. It has been listed since 1 February 2019. In the fiscal year to 31 December 2025, it reported revenue of €7.7m and net income of €15.3m. At that date it held total assets of €6.0m and shareholders' equity of −€9.8m.
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. The company is headquartered in Korneuburg, Niederoesterreich. The company went IPO on 2019-02-01. The firm develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The firm also offers products for the treatment of influenza, combination products for asthmatics, and others. The firm also develops treatments for type I allergies and autoimmune diseases. The firm is a spin-off from the University of Veterinary Medicine, Vienna.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Feb 2019
- Employees
- 44
- Website
- marinomed.com ↗
Leadership
Pay as last reported
- Mr. Simon NebelIndependent Chairman of the Supervisory Board, since 2017
- Mr. Andreas GrassauerChairman of the Executive Board, Chief Executive Officer
- Ms. Ute LassnigIndependent Deputy Chairman of the Supervisory Board, since 2017
- Dipl.-Kfm. Pascal SchmidtChief Financial Officer, Member of the Executive Board
- Ms. Eva Prieschl- GrassauerChief Scientific Officer, Member of the Executive Board
- Ms. Brigitte EdererIndependent Member of the Supervisory Board
- Dr. Gernot HoferIndependent of the Supervisory Board
- Ms. Stephanie KniepHead of Investor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Marinomed Biotech AG develops antiviral and immunological therapies using Marinosolv and Carragelose platforms.
- Marinomed Biotech AG has six products against respiratory viral infections using Carragelose platform.
- Marinomed Biotech AG is a spin-off from University of Veterinary Medicine, Vienna with patent protected technology platforms.
Weaknesses
- Marinomed Biotech AG employs only 44 full-time employees in Korneuburg, Austria.
- Marinomed Biotech AG has no products for cancer treatment or chronic diseases.
- Marinomed Biotech AG's business is limited to respiratory and allergy therapies.
Opportunities
- Marinomed Biotech AG can expand Carragelose platform to new markets in Europe and Asia.
- Marinomed Biotech AG can develop new products for autoimmune diseases using Marinosolv platform.
- Marinomed Biotech AG can partner with larger pharmaceutical companies for global distribution.
Threats
- Marinomed Biotech AG faces competition from established pharmaceutical companies in Health Care sector.
- Marinomed Biotech AG's small employee count may limit research and development capabilities.
- Marinomed Biotech AG's reliance on respiratory and allergy therapies could be affected by changing market demands.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.